A double-blind clinical study in patients with herpes zoster to establish YN-72 (Brovavir) dose.

Abstract

Double-blind clinical trials were performed with a placebo to determine the optimum dose of YN-72 in patients with herpes zoster. YN-72 at 10, 50, and 100 mg was administered orally three times daily for 7 days. A total of 226 patients entered the present trial. Six of the 226 patients were excluded from statistical analysis of data. Furthermore, seven… (More)

Topics

Cite this paper

@article{Niimura1990ADC, title={A double-blind clinical study in patients with herpes zoster to establish YN-72 (Brovavir) dose.}, author={Michihito Niimura}, journal={Advances in experimental medicine and biology}, year={1990}, volume={278}, pages={267-75} }